{"schema_version":"secwatch.filing_event.v1","accession":"0001077183-24-000106","form_type":"8-K","ticker":"NEO","cik":"0001077183","company_name":"NEOGENOMICS INC","filed_at":"2024-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.106055+00:00","generated_at":"2026-05-31T15:37:23.343817+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeoGenomics Q2 revenue $165M (+12% YoY); raises FY2024 EBITDA guidance to $33-37M","bullets":["Q2 revenue $165M (+12% YoY); net loss narrowed 23% to $19M.","Adjusted EBITDA $11M (+630% YoY) vs -$2M in prior-year quarter.","Clinical Services revenue $141M (+15% YoY); Advanced Diagnostics $23M (-3%).","FY2024 guidance raised: revenue $655-667M (from $650-660M); adj. EBITDA $33-37M (from $21-24M).","Cash and marketable securities $388M at quarter end."],"urls":{"canonical":"https://secwatch.observer/filing/0001077183-24-000106","json":"https://secwatch.observer/filing/0001077183-24-000106.json","markdown":"https://secwatch.observer/filing/0001077183-24-000106.md","text":"https://secwatch.observer/filing/0001077183-24-000106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1077183/000107718324000106/0001077183-24-000106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1077183/000107718324000106/neo-20240729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:37:23.343817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}